Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Meningococcal vaccine groups A B C Y W-135 conjugate - GSK

Drug Profile

Meningococcal vaccine groups A B C Y W-135 conjugate - GSK

Alternative Names: GSK-3536819A; GSK3536819; MenABCWY (1st Gen); Meningococcal ABCWY Vaccine; rMenB + MenACWY

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer GSK
  • Class Conjugate vaccines; Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Meningococcal group A infections; Meningococcal group B infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections

Most Recent Events

  • 26 Jul 2023 GSK announces intention to submit regulatory application for Meningococcal group ABCWY infections in European Union in the first half of 2024 (IM)
  • 26 Jul 2023 GSK announces intention to submit regulatory application for Meningococcal group ABCWY infections in USA in the first half of 2024 (IM)
  • 03 May 2023 GlaxoSmithKline completes a phase-III trial in Meningococcal group ABCY infections (In adolescents, Prevention, In adults) in Canada, Argentina, USA and Australia (IM) (NCT04707391) (EudraCT 2019-004982-42)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top